Is access to new medicines improving in Scotland?
Six new medicines have been accepted for use in the NHS in Scotland, including treatments for leukaemia and lung cancer.
Scottish Medicines Consortium recommended five of them after considering them under the PACE (patient and clinician engagement) process for very rare or end-of-life conditions.
These were everolimus (Votubia) for epilepsy in patients with tuberous sclerosis complex; inotuzumab ozogamicin (Besponsa) for acute lymphoblastic leukaemia (ALL); midostaurin (Rydapt) for adults with newly diagnosed acute myeloid leukaemia (AML); crizotinib (Xalkori) for a rare subtype of non-small cell lung cancer; and telotristat ethyl (Xermelo), for severe diarrhoea associated with carcinoid syndrome.
The committee also accepted guselkumab (Tremfya) for the treatment of severe plaque psoriasis in adults.
Further information
Scottish Medicines Consortium: June 2018 decisions news release